NIH SBIR leverage Novoron has secured multiple NIH SBIR grants (including a 2.5M grant and a 1.25M grant) targeting CNS repair and tau pathology, signaling strong validation and potential for continued funded R&D collaborations with federal programs.

Neurodegenerative focus With programs targeting Alzheimer's disease, tau propagation blockers, and brain organoid platforms, there are opportunities to pitch partnerships around drug screening services, collaboration on therapeutic discovery, and access to early-stage CNS models.

Platform potential Development of human iPSC-derived brain organoids provides a scalable platform for screening small molecules, enabling potential license deals or co-development agreements for screening pipelines, neurodegeneration targets, and biomarker discovery.

Strategic visibility Active participation in industry conferences (Biocom Global Life Science Partnering, BIO 2024) and press coverage indicates readiness for investor and partner outreach; leverage event exposure to arrange meetings with biotech funders, pharma alliances, and strategic collaborations.

Financial trajectory Current revenue range and cumulative funding (seed and SBIR grants totaling over 9M) suggest a lean, grant-backed growth profile; explore co-development or milestone-driven partnerships with pharma companies seeking early CNS innovation with risk-sharing funding.